Study of Raludotatug Deruxtecan for Advanced Ovarian Cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests a new drug (raludotatug deruxtecan) with or without another drug (bevacizumab) as maintenance therapy after initial chemotherapy for advanced ovarian cancer. It aims to see if this combination can help keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced ovarian, fallopian tube, or primary peritoneal cancer (Stage III or IV) with a high-grade serous or endometrioid subtype.
- You must have completed initial platinum-based chemotherapy and your disease must not have worsened (stable disease or better).
- You must not have had any prior systemic cancer treatment except the first-line chemotherapy for this cancer.
- You must have recovered from any major surgery before starting the study.
- You must not have any other cancer that is progressing or needs treatment within the last 3 years.
- You must not have active inflammatory bowel disease, a serious lung condition, or a bowel blockage related to your cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, Raludotatug Deruxtecan (R-DXd), given alone or with another drug called bevacizumab, as ongoing treatment after initial chemotherapy for recurrent ovarian cancer. It aims to see if this maintenance treatment helps keep the cancer from coming back longer.
This trial tests a new drug called R-DXd (given alone or with another drug called bevacizumab) for ovarian cancer that has grown while on a PARP inhibitor. The goal is to see if this combination can help control the cancer.
This trial tests whether adding trastuzumab deruxtecan to standard maintenance therapy with bevacizumab works better than bevacizumab alone for people with advanced ovarian cancer that has the HER2 protein. It is for those who have finished initial chemotherapy plus bevacizumab and are now starting maintenance treatment.
This trial compares a targeted drug called trastuzumab deruxtecan to standard treatment for ovarian, fallopian tube, or primary peritoneal cancer that has come back after previous treatment with a PARP inhibitor. The study is for patients whose tumors show a certain level of a protein called HER2 on their surface.
This trial tests adding trastuzumab to standard maintenance therapy with bevacizumab for patients with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. The goal is to see if the combination helps keep the cancer from growing longer.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.